Who Paid My Doc
Vizamyl
Drug Pharma Imaging Agents - Nuclear Imaging
NDC 17156-067-30
General payments
$48,103
Research payments
$108,015
Through program year 2025, $48,103 in general payments and $108,015 in research payments were reported against Vizamyl (Pharma Imaging Agents - Nuclear Imaging).
No combined total These are different kinds of money, reported under different rules. A meal and a clinical trial grant do not add up to anything meaningful, so this site does not add them.
By program year
4 rows| Year | Kind | Amount | Payments |
|---|---|---|---|
| 2025 | General | $21,031 | 15 |
| 2025 | Research | $31,045 | 3 |
| 2024 | General | $27,072 | 10 |
| 2024 | Research | $76,970 | 4 |
Breakdown
Each share is of general payments naming this product in 2025.
Each share is of general payments naming this product to practitioners with a specialty in 2025. Each practitioner is counted under their primary specialty.
Each share is of general payments naming this product in 2025 where a state was reported.
Records
25 general · 7 researchEvery payment, record by record
Date, amount, who was paid and what for — filter by year and kind, or download as CSV, free, in files of 5,000 rows.
What you are looking at
Manufacturers name the drug, biological or device a payment relates to. CMS does not give products their own identifiers, so a product here is assembled from how it was reported — a brand may appear under more than one spelling, and this page covers one of them rather than the brand as a whole.